<DOC>
	<DOCNO>NCT01563042</DOCNO>
	<brief_summary>An exploratory First Time Human ( FTIH ) study investigate pharmacokinetics , immunogenicity , safety tolerability GSK2434735 administer single low dose healthy male subject</brief_summary>
	<brief_title>A Single Dose Pharmacokinetics ( PK ) Study GSK2434735 Healthy Male Volunteers</brief_title>
	<detailed_description>Interleukin-13 ( IL-13 ) IL-4 mediator pathogenesis establish asthmatic disease . GSK2434735 bispecific antibody IL-13 IL-4 . The purpose open label , sequential cohort , exploratory First Time Human ( FTIH ) study evaluate pharmacokinetics ( PK ) profile GSK2434735 single low intravenous subcutaneous dose healthy male volunteer , ass pharmacokinetics ( PK ) parameter scale monkey man . In addition , safety tolerability monitor study ass antibody generate GSK2434735 .</detailed_description>
	<criteria>Healthy male volunteer 18 65 year age Negative preexisting antibody GSK2434735 . Body weight great equal 50 kg BMI 19 29.9 kg/m2 . Lifelong nonsmoker exsmokers great 6 month Clinically significant abnormality . Current past history significant cardiac , respiratory , metabolic , renal , hepatic , neurological gastrointestinal condition . Current evidence recent history infective illness . Vaccination within 3 week screen History severe allergic reaction , angiooedema , anaphylaxis immunodeficiency</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>immunogenicity</keyword>
	<keyword>GSK2434735</keyword>
	<keyword>pharmacokinetics ( PK )</keyword>
	<keyword>PK</keyword>
	<keyword>biospecific antibody</keyword>
</DOC>